Display options
Cite
Paganelli G, De Cicco C, Ferrari ME, et al. IART (Intra-Operative Avidination for Radionuclide Therapy) for accelerated radiotherapy in breast cancer patients. Technical aspects and preliminary results of a phase II study with 90Y-labelled biotin. Ecancermedicalscience. 2010;4:166doi: 10.3332/ecancer.2010.166.
Paganelli, G., De Cicco, C., Ferrari, M. E., McVie, G., Pagani, G., Leonardi, M. C., Cremonesi, M., Ferrari, A., Pacifici, M., Di Dia, A., Botta, F., De Santis, R., Galimberti, V., Luini, A., Orecchia, R., & Veronesi, U. (2010). IART (Intra-Operative Avidination for Radionuclide Therapy) for accelerated radiotherapy in breast cancer patients. Technical aspects and preliminary results of a phase II study with 90Y-labelled biotin. Ecancermedicalscience, 4166. https://doi.org/10.3332/ecancer.2010.166
Paganelli, G, et al. "IART (Intra-Operative Avidination for Radionuclide Therapy) for accelerated radiotherapy in breast cancer patients. Technical aspects and preliminary results of a phase II study with 90Y-labelled biotin." Ecancermedicalscience vol. 4 (2010): 166. doi: https://doi.org/10.3332/ecancer.2010.166
Paganelli G, De Cicco C, Ferrari ME, McVie G, Pagani G, Leonardi MC, Cremonesi M, Ferrari A, Pacifici M, Di Dia A, Botta F, De Santis R, Galimberti V, Luini A, Orecchia R, Veronesi U. IART (Intra-Operative Avidination for Radionuclide Therapy) for accelerated radiotherapy in breast cancer patients. Technical aspects and preliminary results of a phase II study with 90Y-labelled biotin. Ecancermedicalscience. 2010;4:166. doi: 10.3332/ecancer.2010.166. Epub 2010 Nov 01. PMID: 22276027; PMCID: PMC3234029.
Copy Download .nbib Format: NLM
Share it on

Ecancermedicalscience. 2010;4:166. doi: 10.3332/ecancer.2010.166. Epub 2010 Nov 01.

IART (Intra-Operative Avidination for Radionuclide Therapy) for accelerated radiotherapy in breast cancer patients. Technical aspects and preliminary results of a phase II study with 90Y-labelled biotin.

Ecancermedicalscience

G Paganelli, C De Cicco, M E Ferrari, G McVie, G Pagani, M C Leonardi, M Cremonesi, A Ferrari, M Pacifici, A Di Dia, F Botta, R De Santis, V Galimberti, A Luini, R Orecchia, U Veronesi

Affiliations

  1. Division of Nuclear Medicine.

PMID: 22276027 PMCID: PMC3234029 DOI: 10.3332/ecancer.2010.166

Abstract

BACKGROUND: Breast conserving surgery (BCS) plus external beam radiotherapy (EBRT) is considered the standard treatment for early breast cancer. We have investigated the possibility of irradiating the residual gland, using an innovative nuclear medicine approach named IART(®) (Intra-operative Avidination for Radionuclide Therapy).

AIM: The objective of this study was to determine the optimal dose of avidin with a fixed activity (3.7 GBq) of (90)Y-biotin, in order to provide a boost of 20 Gy, followed by EBRT to the whole breast (WB) at the reduced dose of 40 Gy. Local and systemic toxicity, patient's quality of life, including the cosmetic results after the combined treatment with IART(®) and EBRT, were assessed.

METHODS: After tumour excision, the surgeon injected native avidin diluted in 30 ml of saline solution into and around the tumour bed (see video). Patients received one of three avidin dose levels: 50 mg (10 pts), 100 mg (15 pts) and 150 mg (10 pts). Between 12 to 24 h after surgery, 3.7 GBq (90)Y-biotin spiked with 185 MBq (111)In-biotin was administered intravenously (i.v.). Whole body scans and SPECT images were performed up to 30 h post-injection for dosimetric purposes. WB-EBRT was administered four weeks after the IART(®) boost. Local toxicity and quality of life were evaluated.

RESULTS: Thirty-five patients were evaluated. No side effects were observed after avidin administration and (90)Y-biotin infusion. An avidin dose level of 100 mg resulted the most appropriate in order to deliver the required radiation dose (19.5 ± 4.0 Gy) to the surgical bed. At the end of IART(®), no local toxicity occurred and the overall cosmetic result was good. The tolerance to the reduced EBRT was also good. The highest grade of transient local toxicity was G3, which occurred in 3/32 pts following the completion of WB-EBRT. The combination of IART(®)+EBRT was well accepted by the patients, without any changes to their quality of life.

CONCLUSIONS: These preliminary results support the hypothesis that IART(®) may represent a valid approach to accelerated WB irradiation after BCS. We hope that this nuclear medicine technique will contribute to a better management of breast cancer patients.

References

  1. Eur J Nucl Med. 1999 Jun;26(6):606-14 - PubMed
  2. Eur J Nucl Med Mol Imaging. 2007 Jan;34(1):68-77 - PubMed
  3. World J Surg. 1994 Jan-Feb;18(1):70-5 - PubMed
  4. J Clin Oncol. 2007 Aug 1;25(22):3259-65 - PubMed
  5. Ann Surg. 2005 Jul;242(1):101-6 - PubMed
  6. Breast. 2007 Feb;16(1):17-26 - PubMed
  7. Lancet. 1997 Jun 28;349(9069):1864-7 - PubMed
  8. J Nucl Med. 2008 Nov;49(11):1884-99 - PubMed
  9. Phys Med Biol. 1996 Oct;41(10):1871-84 - PubMed
  10. Radiother Oncol. 2008 Apr;87(1):3-16 - PubMed
  11. Cancer Biother Radiopharm. 2001 Jun;16(3):227-35 - PubMed
  12. J Clin Oncol. 2001 Apr 1;19(7):1993-2001 - PubMed
  13. J Exp Clin Cancer Res. 2005 Mar;24(1):109-16 - PubMed
  14. Breast Cancer Res Treat. 2005 Dec;94(3):195-8 - PubMed
  15. Q J Nucl Med Mol Imaging. 2004 Sep;48(3):220-8 - PubMed
  16. Lancet Oncol. 2008 Apr;9(4):331-41 - PubMed
  17. CA Cancer J Clin. 2002 Sep-Oct;52(5):277-300 - PubMed
  18. Int J Radiat Oncol Biol Phys. 2004 Dec 1;60(5):1393-404 - PubMed
  19. Cancer. 1996 Sep 1;78(5):1035-42 - PubMed
  20. Clin Cancer Res. 2007 Sep 15;13(18 Pt 2):5646s-5651s - PubMed
  21. J Surg Oncol. 2002 Jul;80(3):121-8; discussion 129 - PubMed
  22. J Nucl Med. 2005 Jun;46(6):1023-7 - PubMed
  23. N Engl J Med. 2003 Aug 7;349(6):546-53 - PubMed
  24. Int J Radiat Oncol Biol Phys. 2003 Dec 1;57(5):1247-53 - PubMed
  25. Strahlenther Onkol. 2007 Dec;183 Spec No 2:32-4 - PubMed
  26. J Natl Cancer Inst. 1998 Jan 7;90(1):25-9 - PubMed
  27. J Clin Oncol. 2003 Feb 1;21(3):555-63 - PubMed
  28. J Natl Cancer Inst. 2000 Feb 2;92(3):269-71 - PubMed
  29. Semin Radiat Oncol. 2005 Apr;15(2):84-91 - PubMed
  30. J Nucl Med. 1996 Jan;37(1):55-61 - PubMed
  31. N Engl J Med. 2002 Oct 17;347(16):1227-32 - PubMed
  32. J Clin Oncol. 2006 Feb 10;24(5):823-34 - PubMed

Publication Types